S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer

Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma, key data from NAPOLI 3, and the potential evolution of NALIRIFOX’s role in the treatment of patients with pancreatic cancer.